TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
LTR Pharma Limited ( (AU:LTP) ) has issued an update.
LTR Pharma Limited has appointed Dr. Andrew Y. Sun, a renowned urologist and expert in male sexual health, to its Scientific Advisory Board to support the U.S. launch of its intranasal therapies, ROXUS® and SPONTAN®. This strategic move is aimed at capturing a share of the $3.7 billion erectile dysfunction market by offering alternatives for patients intolerant to oral PDE5 inhibitors. Dr. Sun’s extensive experience and influence in the field are expected to enhance prescriber adoption and position LTR Pharma’s products as preferred options, ahead of the planned commercial launch in the first half of 2026.
More about LTR Pharma Limited
LTR Pharma is an emerging pharmaceutical company focused on developing and commercializing innovative therapies to address significant unmet medical needs. The company utilizes a proprietary intranasal drug delivery platform to provide rapid, non-invasive treatment options across various therapeutic areas. Its leading products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for erectile dysfunction, and it is also developing OROFLOW® for Oesophageal Motility Disorders.
Average Trading Volume: 511,577
Technical Sentiment Signal: Sell
See more data about LTP stock on TipRanks’ Stock Analysis page.